Technetium-99m-HMPAO in Tourette's syndrome on neuroleptic therapy and after withdrawal

被引:0
|
作者
Lampreave, JL
Molina, V
Mardomingo, MJ
Bittini, A
Domínguez, P
Almoguera, I
Rubia, FJ
Carreras, JL
机构
[1] Hosp Gen Gregorio Maranon, Dept Nucl Med, E-28009 Madrid, Spain
[2] Hosp Gen Gregorio Maranon, Dept Psychiat, E-28009 Madrid, Spain
[3] Hosp Gen Gregorio Maranon, Infantile Psychiat Dept, E-28009 Madrid, Spain
[4] Univ Complutense Madrid, Brain Mapping Unit, Madrid, Spain
[5] Univ Complutense Madrid, Dept Radiol, Madrid, Spain
[6] Univ Complutense Madrid, PET Ctr, Madrid, Spain
关键词
Tourette's syndrome; brain perfusion; neuroleptic treatment; technetium-99m-HMPAO;
D O I
暂无
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Both decreased and increased perfusion and metabolism have been described with PET and SPECT in different areas of the brain in patients with Gilles de la Tourette's syndrome, The aim of this study was to define the regional cerebral perfusion pattern in drug-free patients and the changes in perfusion with the usual neuroleptic treatment, Methods: A group of 13 normal control subjects and 15 unmedicated Gilles de la Tourette's syndrome patients were studied with Tc-99m-HMPAO brain SPECT. Thirteen of the initial group of patients were retested on neuroleptic treatment. A semiquantitative analysis of the images was performed. Results: Decreased perfusion in orbital and anterior medial regions of both frontal lobes as well as in both temporal lobes was observed in the nontreated group compared with control subjects, With treatment, a perfusion increase in these frontal regions and in the left medial temporal cortex was observed. Conclusion: Neuroleptic treatment could decrease the hyperactivity of the dopaminergic system leading to improvement of the clinical symptoms and reperfusion of some previously hypoperfused regions.
引用
收藏
页码:624 / 628
页数:5
相关论文
共 50 条
  • [21] Technetium-99m-HMPAO SPECT in patients with hemiconvulsions followed by Todd's paralysis
    M. Kimura
    Hitoshi Sejima
    Hiroshi Ozasa
    Seiji Yamaguchi
    Pediatric Radiology, 1998, 28 : 92 - 94
  • [22] INVIVO QUALITY-CONTROL OF TECHNETIUM-99M-HMPAO - REPLY
    BRANDAU, W
    SCHOBER, O
    JOURNAL OF NUCLEAR MEDICINE, 1991, 32 (06) : 1317 - 1317
  • [23] DETERMINATION OF BRAIN-DEATH WITH TECHNETIUM-99M-HMPAO - REPLY
    DRIEDGER, AA
    JOURNAL OF NUCLEAR MEDICINE, 1990, 31 (12) : 2076 - 2076
  • [24] Technetium-99m-HMPAO brain SPECT in neonates with hypoglycemic encephalopathy
    Chiu, NT
    Huang, CC
    Chang, YC
    Lin, CH
    Yao, WJ
    Yu, CY
    JOURNAL OF NUCLEAR MEDICINE, 1998, 39 (10) : 1711 - 1713
  • [25] CORRECTION FOR ATTENUATION IN TECHNETIUM-99M-HMPAO SPECT BRAIN IMAGING
    KEMP, BJ
    PRATO, FS
    DEAN, GW
    NICHOLSON, RL
    REESE, L
    JOURNAL OF NUCLEAR MEDICINE, 1992, 33 (10) : 1875 - 1880
  • [26] METHODOLOGICAL FEATURES FOR NEUROSTIMULATION STUDIES WITH TECHNETIUM-99M-HMPAO SPECT
    LESCAO, Y
    TURZO, A
    MORIN, PP
    BAULIEU, JL
    JOURNAL OF NUCLEAR MEDICINE, 1993, 34 (07) : 1217 - 1217
  • [27] FUNCTIONAL DEFICITS IN AUTISTIC DISORDER - CHARACTERIZATION BY TECHNETIUM-99M-HMPAO AND SPECT
    MOUNTZ, JM
    TOLBERT, LC
    LILL, DW
    KATHOLI, CR
    LIU, HG
    JOURNAL OF NUCLEAR MEDICINE, 1995, 36 (07) : 1156 - 1162
  • [28] Technetium-99m-HMPAO leucocyte labelling in OFG and intestinal Crohn's disease.
    Gibson, J
    Wray, J
    Neilly, B
    Evans, J
    Mackenzie, R
    McKillop, J
    JOURNAL OF DENTAL RESEARCH, 1998, 77 : 895 - 895
  • [29] INCREASED TECHNETIUM-99M-HMPAO UPTAKE IN GRADE-II ASTROCYTOMA
    GRUNWALD, F
    MENZEL, C
    PIETSCH, T
    PAVICS, L
    HUFNAGEL, A
    BIERSACK, HJ
    JOURNAL OF NUCLEAR MEDICINE, 1995, 36 (05) : 804 - 806
  • [30] INTRASUBJECT COMPARISON BETWEEN TECHNETIUM-99M-ECD AND TECHNETIUM-99M-HMPAO IN HEALTHY-HUMAN SUBJECTS
    LEVEILLE, J
    DEMONCEAU, G
    WALOVITCH, RC
    JOURNAL OF NUCLEAR MEDICINE, 1992, 33 (04) : 480 - 484